The objective of this study was to determine whether the mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) expression can differentiate pancreatic ductal adenocarcinoma (PDA) from chronic pancreatitis (CP) and to analyze its biological and clinical significance in PDA. We have previously found by gene array analysis that MAP4K4 is overexpressed in PDA tissues. Here, we measured MAP4K4 gene and protein expression in 58 PDA and 9 CP surgical specimens using RT-PCR and immunohistochemistry, and analyzed their association with clinical outcomes. MAP4K4 mRNA expression was significantly higher in PDA versus CP tissues (Mann Whitney test, p<0.003), and correlated with TNM stage (Kruskal-Wallis test, p£0.026). MAP4K4 protein expression was significantly correlated with tumor grade (Spearman's Rho = 0.449, p£0.01), and tended to associate with shorter overall survival (p£0.076, log-rank test). In conclusion, our data indicate that the level of MAP4K4 expression directly correlates with PDA progression. Thus these data suggest that MAP4K4 may be a biomarker and potentially a target for therapy in PDA.
INTRODUCTION INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) remains a major health problem. Yearly, PDA incidence closely matches its mortality, highlighting the limited efficacy of existing treatment options (1, 2) . The prognosis of pancreatic cancer is extremely poor, with an overall 5-year survival of less than 5%, mainly because of the late onset of disease-specific symptoms and a shortage of good targets and biomarkers for the disease (3) .
By combining gene expression analyses of wholetissue and microdissected PDA, we previously identified the mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) as one of the gene specifically overexpressed in PDA (4) . The MAP4K4 gene encodes for the MAP4K4 protein, a member of the mitogenactivated protein kinases family (MAPK). MAPK signaling pathways are commonly activated through phosphorylation cascades downstream growth factor receptors and promote cell proliferation and survival (5-7). The MAP4K4 gene encodes an upstream activator of the JNK pathway, which is involved in cellular responses to stress and cell apoptosis (8, 9) . Moreover, the function of MAP4K4 appears to be linked to the response to environmental stress and cytokines such as tumor necrosis factor-α (TNF-α). TNF-α is released in the microenvironment predominantly by infiltrating macrophages and participates in the chronic inflammation associated with PDA (10, 11) .
The aim of the present study was to analyze MAP4K4 expression at the mRNA and protein level in surgical specimens from PDA patients. We examined whether MAP4K4 expression could differentiate PDA from chronic pancreatitis (CP) and if it is associated with clinical outcome.
METHODS METHODS

Patients
The study included 58 patients with PDA and 9 with chronic pancreatitis, who underwent pancreatic resection at the Center of Digestive Disease and Liver Transplantation of Fundeni Clinical Institute, Bucharest, Romania, between [2003] [2004] [2005] [2006] [2007] [2008] . None of the patients received neoadjuvant therapy. All patients provided informed, written consent for the use of their samples, and the study was approved by the Ethics Committee of Fundeni Clinical Institute Bucharest, Romania, in accordance with ethical standards included in the current revision of the Helsinki Declaration. Clinicopathologic and follow-up data were gathered retrospectively for each case from the patient's medical records. Post-operative survival was measured from the day of surgery to death or the date of last follow-up visit.
Pancreatic tissues specimens
Tissue samples were collected at the time of surgery from all PDA and CP patients. Each specimen was cut in at least two pieces and one was stored at −80°C and one was formalin-fixed and paraffin-embedded. The gross pathological features analyzed were the size of the tumor, presence or absence of tumor necrosis and regional lymph involvement. All patient samples were coded to protect patients' confidentiality. The diagnosis, histological typing, grading and staging were independently evaluated by two experienced gastrointestinal pathologists (V.H. and C.P.). The tumor node metastasis (TNM) staging was defined according to the International Union Against Cancer criteria (12) .
Immunohistochemical analysis
The MAP4K4 protein expression was analyzed in PDA samples in intratumoral areas, peritumoral areas (junction area) and non-tumoral areas (normal tissue) by immunostaining. We used anti-MAP4K4 antibody (Sigma-Aldrich, Saint Louis, USA, catalog number HP008476) and DAKO Envision Dual Link as detection system, following the manufacturer's recommendations. High expression of MAP4K4 (MAP4K4-H) was defined as cytoplasmic staining of ≥ 10% of the tumor cells, and low expression of MAP4K4 (MAP4K4-L) was defined as cytoplasmic staining of < 10% of the tumor cells or no cytoplasmic staining, as previously reported (13, 14) .
RNA extraction and cDNA synthesis
Total RNA was extracted from snap frozen pancreatic tissue specimens and PDA cells using the Tri Reagent TM (Sigma-Aldrich, USA). The concentration of each total RNA sample was measured with a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, USA). RNA integrity was determined by capillary electrophoresis with an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, USA), and the extracted RNA was accepted for experiments if the RNA integrity number was over 7.0. First strand cDNA synthesis was performed using MultiScribe TM reverse transcriptase and random primers (Applied Biosystems, USA) according to manufacturer indications.
Quantitative RT-PCR
The cDNA was analyzed by quantitative RT-PCR using an Applied Biosystems Sequence Detection System 7300 and TaqMan® Gene Expression Assays Protocol (Applied Biosystems). For the amplification of the cDNA, TaqMan® gene expression assays with MAP4K4 predesigned primers and probe sets (ID Hs00377410_m1, Applied Biosystems) were used. All 58 PDA samples were analyzed in triplicate, against the reference gene 18S RNA. Gene expression levelswere assessed by analyzing threshold cycle (Ct)
values for each sample. Gene expression levels were calculated for each gene using double normalization method (ΔΔCt).
Statistical analysis
Descriptive statistical measures, including the mean ± standard deviation, median and range, were calculated. Data are presented as mean ± SD unless otherwise specified; because the data distribution did not follow a Gaussian curve on preliminary statistical analysis, the comparisons between groups were performed using nonparametric significance tests (Mann-Whitney U test and Kruskal-Wallis test). The gene or protein expression of MAP4K4 was analyzed based on clinicopathologic split variables, including degree of differentiation, tumor size, tumor grade and lymph node invasion. In addition, correlations between different measurements were investigated using the Spearman's Rho correlation coefficient. Survival distributions were calculated using the Kaplan-Meier product-limit method and compared by log-rank test. Comparisons with a p value of less than 0.05 were considered statistically significant. The effects of gene silencing, proliferation and migratory capacity were analyzed using Student t-test. All statistical analyses were performed with SPSS version 17.0 software (SPSS, Chicago, IL).
RESULTS RESULTS
Patient characteristics
Patient demographics are listed in table 1. Our study included tissue from 58 patients with PDA (33 men and 25 women) with mean age at diagnosis 61.6 years (range, 43-77 years). The mean tumor diameter was 2.89 cm (range, 0.3-8 cm). According to the AJCCE classification, PDA was stage I in 18 patients (31%), stage II A in 7 patients (12%), IIB in 26 patients (45%) and stage III/IV in 7 patients (12%). 32 (55%) of PDA patients had lymph node metastases. As a control, we studied tissues from 9 patients (4 men and 5 women) with pathologically confirmed CP. The mean age at diagnosis for the CP group was 58 years (range: 45-79 years).
MAP4K4 expression is higher in PDA and is associated with tumor grade
We found a significantly higher mRNA MAP4K4 expression in PDA tissue compared to pancreatic tissue from CP patients (Mann Whitney test, p £ 0.003) ( fig. 1) was statistically significant correlated with tumor grade (Spearman's Rho = 0.449, p = 0.01). Thus, the expression of the MAP4K4 protein appears to increase with PDA progression. 
MAP4K4 expression tends to associate with poor survival in PDA patients
All patients were followed up for an average of 18 months (range 2-90 months). Of the 58 PDA patients, five patients were alive at the census date. The KaplanMeier survival distributions showed that PDA patients with high MAP4K4 protein expression tended to have shorter survival compared to those with low protein expression (p=0.072, log rank test) ( fig. 2) . The median overall survival was 11 months for PDA patients whose tumors were MAP4K4-H (n=40), and 25 months for PDA patients whose tumors with MAP4K4-L (n=13).
DISCUSSION DISCUSSION
Recent studies have shown that MAP4K4 is increased in different types of human cancer tissue and cell lines (4, 15, 16) . We have previously shown that that MAP4K4 is over-expressed in PDA tissue using gene array (4) . Here, we investigated the role and the prognostic significance of MAP4K4 in PDA patients and examined the role of MAP4K4 in PDA cells.
We first confirmed the overexpression of MAP4K4 in PDA both at the mRNA and protein levels compared to adjacent non-tumor pancreatic tissue. Moreover, we show that MAP4K4 expression increased with tumor The MAPK pathway has been previously involved PDA progression. Blocking the upstream receptor (EGFR) activation was the first targeted therapy approach that led to increased survival in PDA patients (17) . Handra-Luca et al. suggested that MKK4 is directly related to high cell proliferation, and that tumor ERK1/2 and P38MAPK expression correlated to shorter postsurgical recurrence-free and overall survival rates. They reported that MKK4 expression was correlated with advances tumor stages N1 and T3 TNM, and with high Ki-67 index, suggesting that MKK4 is involved in cell proliferation (18) .
Despite increasing evidence that MAP4K4 is a poor prognostic factor in PDA, little is known about its function. The main activators of MAP4K4 are stressrelated factors and proinflammatory cytokines such as TNF- (19) . Indeed, we have recently reported that increase in blood circulating proinflammatory cytokines is a poor prognostic factor PDA patients (20) . In other malignancies, it has been shown that MAP4K4 can directly activated JNK through TAK1, MKK4, and MKK7 (21) . JNK family plays crucial roles in regulating responses to various stresses, inflammation, and apoptosis (22) . MAP4K4 has also been reported to activate a number of other proteins, including kinases within the JAK/STAT pathway that sustain cell proliferation and angiogenesis (15) . Based on data using silencing of the MAP4K4 expression in hepatocellular carcinoma, Liu et al. suggested that MAP4K4 is a key player in the progression of this cancer by increasing cell viability (14) .
CONCLUSION CONCLUSION
In conclusion, our data indicate that MAP4K4 expression is selectively upregulated in malignant versus chronically inflamed pancreatic tissues and its mRNAlevel directly correlates with tumor grade and with a poor outcome in PDA patients. The biological significance of MAP4K4 explored by knocking down its expression revealed that MAP4K4 appears to primarily mediate cell invasion. Collectively, these data suggest that MAP4K4 may be a biomarker and potentially a target for therapy in PDA. Further studies are necessary to investigate this hypothesis. 
